Changes in Hong Kong stocks | Sihuan Pharmaceutical (00460) rose nearly 4% in the morning, Xuanzhu Biotech and INNOBIC reached a commercial cooperation on piroxil in the Thai market

The Zhitong Finance App learned that Sihuan Pharmaceutical (00460) rose nearly 4% in the morning. As of press release, it had risen 3.92% to HK$0.795, with a turnover of HK$9.813 million.

According to the news, on September 3, Sihuan Pharmaceutical announced that recently Xuanzhu Biotechnology Co., Ltd. (Xuanzhu Biotech, 02575), a non-wholly-owned subsidiary of the Japanese Group, and Thai pharmaceutical companies Innobic (Asia) Co., Ltd. (Innobic (Asia)) and ZaoAn International Trading Co., Ltd. (Good Morning International) signed a tripartite commercial agreement (this agreement) for the piroxilide tablets (target product) of Xuanzhu Biotech. The term of the agreement is until June 30, 2036 Term expires.

According to the agreement, Xuanzhu Biotech has jointly granted exclusive commercialization rights for target products within the Thai region (target region) to Innobic (Asia). Such commercialization rights include the right to import, promote, market, offer sale, and distribute target products within the target region. Innobic (Asia) will act as a distributor and be responsible for drug registration, local marketing and commercial operation of target products in target regions. Under the agreement, the listing license for the target product will be held in the name of Innobic (Asia). Good Morning International will act as an intermediary and bear the main responsibility for payments under the purchase order. Xuanzhu Biotech will supply target products at agreed supply prices to support commercialization activities of target products in target regions.